Legal & General Group PLC Rhythm Pharmaceuticals, Inc. Transaction History

Legal & General Group PLC

$357 Billion
Q1 2025

A detailed history of Legal & General Group PLC transactions in Rhythm Pharmaceuticals, Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 51,158 shares of RYTM stock, worth $3.03 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

51,158

Previous 51,803 1.25%

Holding current value

$3.03 Million

Previous $2.9 Million 6.42%

% of portfolio

0.0%

Previous 0.0%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$48.56 - $61.02 $31,321 - $39,357	-645 Reduced 1.25%	51,158 $2.71 Million
Q4 2024 Feb 13, 2025	SELL	$46.91 - $67.33 $199,086 - $285,748	-4,244 Reduced 7.57%	51,803 $2.9 Million
Q3 2024 Feb 28, 2025	SELL	$40.81 - $55.0 $38,810 - $52,305	-951 Reduced 1.84%	50,852 $2.66 Million
Q3 2024 Nov 14, 2024	BUY	$40.81 - $55.0 $102,882 - $138,655	2,521 Added 4.71%	56,047 $2.94 Million
Q2 2024 Aug 14, 2024	BUY	$35.41 - $44.37 $216,355 - $271,100	6,110 Added 12.89%	53,526 $2.2 Million
Q1 2024 May 14, 2024	BUY	$39.12 - $52.44 $23,002 - $30,834	588 Added 1.26%	47,416 $2.05 Million
Q4 2023 Feb 15, 2024	BUY	$21.39 - $49.64 $78,586 - $182,377	3,674 Added 8.51%	46,828 $2.15 Million
Q3 2023 Nov 14, 2023	BUY	$15.81 - $27.8 $7,920 - $13,927	501 Added 1.17%	43,154 $989,000
Q2 2023 Aug 14, 2023	BUY	$16.32 - $21.15 $416,714 - $540,044	25,534 Added 149.16%	42,653 $703,000
Q1 2023 May 15, 2023	BUY	$16.88 - $34.24 $39,212 - $79,539	2,323 Added 15.7%	17,119 $305,000
Q4 2022 Feb 14, 2023	BUY	$22.21 - $30.25 $111,671 - $152,097	5,028 Added 51.47%	14,796 $430,000
Q3 2022 Nov 14, 2022	SELL	$4.3 - $30.85 $10,659 - $76,477	-2,479 Reduced 20.24%	9,768 $239,000
Q2 2022 Aug 22, 2022	SELL	$3.12 - $12.25 $3,169 - $12,446	-1,016 Reduced 7.66%	12,247 $51,000
Q3 2021 Nov 15, 2021	BUY	$11.68 - $20.72 $79,552 - $141,123	6,811 Added 105.56%	13,263 $173,000
Q2 2021 Aug 12, 2021	SELL	$18.52 - $22.55 $74 - $90	-4 Reduced 0.06%	6,452 $127,000
Q1 2021 May 17, 2021	BUY	$20.25 - $39.49 $27,033 - $52,719	1,335 Added 26.07%	6,456 $137,000
Q4 2020 Feb 12, 2021	SELL	$21.17 - $32.61 $1,185 - $1,826	-56 Reduced 1.08%	5,121 $152,000
Q3 2020 Nov 13, 2020	SELL	$18.13 - $30.61 $26,524 - $44,782	-1,463 Reduced 22.03%	5,177 $112,000
Q2 2020 Aug 14, 2020	BUY	$14.41 - $25.35 $11,513 - $20,254	799 Added 13.68%	6,640 $148,000
Q1 2020 May 14, 2020	SELL	$13.16 - $22.9 $17,147 - $29,838	-1,303 Reduced 18.24%	5,841 $85,000
Q4 2019 Feb 13, 2020	BUY	$19.53 - $25.5 $57,164 - $74,638	2,927 Added 69.41%	7,144 $164,000
Q2 2019 Aug 14, 2019	BUY	$21.11 - $28.48 $28,751 - $38,789	1,362 Added 47.71%	4,217 $93,000
Q1 2019 May 15, 2019	BUY	$24.76 - $31.66 $4,456 - $5,698	180 Added 6.73%	2,855 $79,000
Q3 2018 Nov 20, 2018	BUY	$26.99 - $35.85 $22,941 - $30,472	850 Added 46.58%	2,675 $78,000
Q2 2018 Aug 10, 2018	BUY	$17.02 - $35.2 $6,518 - $13,481	383 Added 26.56%	1,825 $57,000
Q4 2017 Feb 13, 2018	BUY	$22.0 - $30.51 $31,724 - $43,995	1,442	1,442 $42,000

Others Institutions Holding RYTM

# of Institutions

245

Shares Held

62.9M

Call Options Held

403K

Put Options Held

62.8K

View Full List

About RHYTHM PHARMACEUTICALS, INC.

Ticker RYTM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,720,000
Market Cap $3.3B
Description
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...

More about RYTM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.

Account

Legal & General Group PLC Rhythm Pharmaceuticals, Inc. Transaction History